288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors

• Bhumsuk Keam,
• Chan-Young Ock,
• Tae Min Kim,
• Do-Youn Oh,
• Jeeyun Lee,
• Won Ki Kang,
• Yeon Hee Park,
• Ji Hye Lee,
• Yun Jeong Song,
• Young Suk Park

Affiliations

Bhumsuk Keam

7 Seoul National University Hospital, Seoul, South Korea

Chan-Young Ock

1Seoul National University Hospital, Seoul, Korea, Republic of

Tae Min Kim

1Seoul National University Hospital, Seoul, Korea, Republic of

Do-Youn Oh

1Seoul National University Hospital, Seoul, Korea, Republic of

Jeeyun Lee

Aff211 grid.264381.a000000012181989XSamsung Medical CenterSungkyunkwan University School of Medicine Seoul South Korea

Won Ki Kang

Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Yeon Hee Park

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Ji Hye Lee

3ImmuneOncia Therapeutics Inc., Gyeonggi-do, Korea, Republic of

Yun Jeong Song

3ImmuneOncia Therapeutics Inc., Gyeonggi-do, Korea, Republic of

Young Suk Park

2Samsung Medical Center, Seoul, Korea, Republic of